Citizens JMP analyst Constantine Davides raised the firm’s price target on OptimizeRx (OPRX) to $24 from $23 and keeps an Outperform rating on the shares. OptimizeRx showed continuing momentum in Q3 and established formal guidance for 2026, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Reports Strong Q3 Growth and Raises Guidance
- OptimizeRx: Strong Financial Performance and Promising Outlook Justify Buy Rating
- OptimizeRx reports Q3 EPS 20c, consensus 5c
- OptimizeRx raises FY25 revenue view to $105M-$109M from $104M-$108M
- OptimizeRx sees FY26 revenue $118M-$124M, consensus $119.19M